Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ActogeniX NV Snapshot 5
ActogeniX NV Overview 5
Key Information 5
Key Facts 5
ActogeniX NV – Research and Development Overview 6
Key Therapeutic Areas 6
ActogeniX NV – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
ActogeniX NV – Pipeline Products Glance 10
ActogeniX NV Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
ActogeniX NV – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
ActogeniX NV – Drug Profiles 13
ActoBiotic For Celiac Disease 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
ActoBiotic For Clostridium Difficile Enteropathy 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
ActoBiotics For Type 1 Diabetes 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ActoBiotics For Type 2 Diabetes 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
ActoGeniX For Allergic Disease 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AG013 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AG014 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Interleukin-27 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
L.lactis-Antibodies 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ActogeniX NV – Pipeline Analysis 22
ActogeniX NV – Pipeline Products by Therapeutic Class 22
ActogeniX NV – Pipeline Products By Target 24
ActogeniX NV – Pipeline Products by Route of Administration 25
ActogeniX NV – Pipeline Products By Mechanism of Action 26
ActogeniX NV – Recent Pipeline Updates 27
ActogeniX NV - Dormant Projects 28
ActogeniX NV – Locations And Subsidiaries 29
Head Office 29
ActogeniX NV, Recent Developments 30
ActogeniX NV- Press Release 30
Oct 09, 2009: ActoGeniX Completes Phase IIA Clinical Trial Of AG011 30
Aug 20, 2009: ActoGeniX Receives IWT Grant For Treatment Of Oral Mucositis And Starts Clinical Trial With AG013 30
May 14, 2009: ActoGeniX Receives IND Approval For AG013 31
Financial Deals Landscape 32
ActogeniX NV, Deals Summary 32
ActogeniX NV, Pharmaceuticals & Healthcare, Deal Details 33
Venture Financing 33
ActoGeniX Secures $20 Million In Venture Financing 33
ActoGeniX Secures Additional $11 Million In Series A Financing 36
ActoGeniX Secures $15 Million In Series A Financing 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41
List of Tables
ActogeniX NV, Key Information 5
ActogeniX NV, Key Facts 5
ActogeniX NV – Pipeline by Indication, 2012 7
ActogeniX NV – Pipeline by Stage of Development, 2012 8
ActogeniX NV – Monotherapy Products in Pipeline, 2012 9
ActogeniX NV – Phase II, 2012 10
ActogeniX NV – Pre-Clinical, 2012 11
ActogeniX NV – Discovery, 2012 12
ActogeniX NV – Pipeline By Therapeutic Class, 2012 23
ActogeniX NV - Pipeline By Target, 2012 24
ActogeniX NV – Pipeline By Route of Administration, 2012 25
ActogeniX NV – Pipeline Products By Mechanism of Action, 2012 26
ActogeniX NV – Recent Pipeline Updates, 2012 27
ActogeniX NV - Dormant Developmental Projects,2012 28
ActogeniX NV, Deals Summary 32
ActoGeniX Secures $20 Million In Venture Financing 33
ActoGeniX Secures Additional $11 Million In Series A Financing 36
ActoGeniX Secures $15 Million In Series A Financing 38
List of Figures
ActogeniX NV – Pipeline by Indication, 2012 7
ActogeniX NV – Pipeline by Stage of Development, 2012 8
ActogeniX NV – Monotherapy Products in Pipeline, 2012 9
ActogeniX NV – Pipeline By Therapeutic Class, 2012 22
ActogeniX NV - Pipeline By Target, 2012 24
ActogeniX NV - Pipeline Products By Mechanism of Action, 2012 26